Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q14019
UPID:
COTL1_HUMAN
Alternative names:
-
Alternative UPACC:
Q14019; B2RDU3; D3DUL9; Q86XM5
Background:
Coactosin-like protein, identified by the accession number Q14019, plays a pivotal role in cellular processes through its ability to bind to F-actin in a calcium-independent manner. It does not directly affect actin depolymerization but acts as a chaperone for ALOX5, crucial in leukotrienes synthesis, thereby influencing both its stability and activity.
Therapeutic significance:
Understanding the role of Coactosin-like protein could open doors to potential therapeutic strategies. Its involvement in leukotrienes synthesis suggests a possible impact on inflammatory processes, making it a target of interest in the development of anti-inflammatory drugs.